本次公布结果的MARKET试验是一项双盲、安慰剂为对照组的试验，用以检验口服AMT-101与adalimumab在中重度溃疡性结肠炎病患联合使用的安全性与疗效性 ...

2021年12月20日讯 / 生物谷 BIOON/ --美国 生物仿制药 公司Coherus BioSciences近日宣布，美国食品和药物管理局（FDA）已批准Yusimry（adalimumab-aqvh，阿达木单抗 ...

Etanercept, adalimumab and infliximab all specifically antagonize tumor necrosis factor (TNF), but with differential clinical efficacy. Differences in their pharmacology and mechanisms of action ...

Adalimumab treatment was reintroduced in January 2005. For safety reasons, the patient has been closely monitored since the resumption of adalimumab therapy, and attends follow-up visits every 3 ...

ABBV-3373是由艾伯维开发的一种研究性ADC，由一种新型的糖皮质激素受体调节剂（GRM）连接到阿达木单抗（adalimumab），目的是通过将糖皮质激素有效 ...

Adalimumab products have not been formally studied in patients with CHF; however, in clinical trials of another TNF blocker, a higher rate of serious CHF-related adverse reactions was observed.

The 7 FDA-approved biosimilars for adalimumab are currently for the original concentration of adalimumab. That's been on the market at 50 mg and is now considered the low concentration version.

Adalimumab was associated with larger improvements from baseline than placebo; these differences were statistically significant, as measured by the EQ‑5D, the physical components of SF‑36, DLQI and ...

4 Committee discussion The appraisal committee reviewed the data available on the clinical and cost effectiveness of adalimumab and dexamethasone intravitreal implant. It considered evidence on the ...

Adalimumab is the only biologic approved for HS, but it displays a clinical response rate of up to 60%, leaving many in need of other treatment options like surgery.

Upadacitinib is equivalent or superior to adalimumab in improving patient-reported outcomes among those with rheumatoid arthritis and an inadequate response to methotrexate, according to data ...

Another adalimumab biosimilar developed by Boehringer Ingelheim, trade-named Cyltezo, gained interchangeability status last October, but its trial was conducted in psoriasis patients.